Le Registre des lobbyistes
| Objets | Détails | Catégories |
|---|---|---|
|
Sciences et technologies
|
Communicating, in general, with government officials about research, development and innovation in Canada's biomedical and biotechnology sector.
|
Politique ou Programme
|
|
Santé, Impôts et finances
|
Communicating with government officials about a national pharmaceutical strategy, more specifically as it relates to (i) enhanced access to orphan drugs and (i) incentives for the development of rare disorder treatments.
|
Politique ou Programme
|
|
Santé, Travail
|
Communicating with government officials about federal healthcare plans and benefits.
|
Politique ou Programme
|
|
Santé
|
Communicating with government officials about programs, reports, reviews and policies issued by or related to Canada's Drug Agency (formerly known as the Canadian Agency for Drugs and Technologies in Health).
|
Politique ou Programme
|
|
Santé, Propriété intellectuelle
|
Communicating with government officials about regulations, guidelines, reviews, references and reporting requirements issued by and/or related to the Patented Medicine Prices Review Board ("PMPRB").
|
Politique ou Programme
|
|
Santé, Propriété intellectuelle
|
Communicating with government officials about regulations related to patented medicines, including the "Patented Medicines (Notice of Compliance) Regulations" (SOR/93-133) under the Patent Act.
|
Règlement
|
|
Santé
|
Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.
|
Proposition législative, Projet de loi ou résolution
|
|
Sciences et technologies
|
Communicating with government officials about the Government of Canada's "Biomanufacturing and Life Sciences Strategy" (2021).
|
Politique ou Programme
|
|
Santé, Sciences et technologies
|
Communicating with government officials about the pan-Canadian Health Data Strategy, more specifically about health data foundations.
|
Politique ou Programme
|
Amgen Canada Canada Inc. serves patients throughout Canada by delivering vital medicines to them. The company also contributes to the development of new therapies (and new uses for existing medicines) in partnership with many of Canada’s leading health care, academic, research, government and patient organizations.
Ugur Gunaydin, General Manager, Canada
Adresse :
6775 Financial Drive
Mississauga, ON L5N 0A4
Canada
Numéro de téléphone :
905-285-3000
Numéro de fax :
905-285-3100
Amgen Canada Inc. ne possède aucune filiale qui pourrait être directement intéressée au résultat de l'engagement